Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of liposomal mitoxantrone hydrochloride injection (HE071) in NMOSD
CTR20222744Phase 2Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by CSPC Zhongnuo Pharmaceutical. Started Nov 2022; status: active.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20222744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222744.